Third-generation cephalosporins are widely used ‚-lactam antibiotics that resist hydrolysis by‚-lactamases. Recently, mutant ‚-lactamases that rapidly inactivate these drugs have emerged. To investigatewhy third-generation cephalosporins are relatively stable to wild-type class C ‚-lactamases and how mutantenzymes might overcome this, the structures of the class C ‚-lactamase AmpC in complex with the thirdgenerationcephalosporin ceftazidime and with a transition-state analogue of ceftazidime were determinedby X-ray crystallography to 2.0 and 2.3 Å resolution, respectively. Comparison of the acyl-enzyme structuresof ceftazidime and loracarbef, a ‚-lactam substrate, reveals that the conformation of ceftazidime in theactive site differs from that of substrates. Comparison of the structures of the acyl-enzyme intermediateand the transition-state analogue suggests that ceftazidime blocks formation of the tetrahedral transitionstate, explaining why it is an inhibitor of AmpC. Ceftazidime cannot adopt a conformation competent forcatalysis due to steric clashes that would occur with conserved residues Val211 and Tyr221. The X-raycrystal structure of the mutant ‚-lactamase GC1, which has improved activity against third-generationcephalosporins, suggests that a tandem tripeptide insertion in the ø loop, which contains Val211, hascaused a shift of this residue and also of Tyr221 that would allow ceftazidime and other third-generationcephalosporins to adopt a more catalytically competent conformation. These structural differences mayexplain the extended spectrum activity of GC1 against this class of cephalosporins. In addition, thecomplexed structure of the transition-state analogue inhibitor (Ki 20 nM) with AmpC reveals potentialopportunities for further inhibitor design.
The structures of Ceftazidime and Its Transition State Analog in Complex with AmpC-beta-lactamase: Implication for Resistance Mutation and Inhibitor Design / R. A., Powers; Caselli, Emilia; P. J., Focia; Prati, Fabio; B. K., Shoichet. - In: BIOCHEMISTRY. - ISSN 0006-2960. - STAMPA. - 40:31(2001), pp. 9207-9214. [10.1021/bi0109358]
The structures of Ceftazidime and Its Transition State Analog in Complex with AmpC-beta-lactamase: Implication for Resistance Mutation and Inhibitor Design
CASELLI, Emilia;PRATI, Fabio;
2001
Abstract
Third-generation cephalosporins are widely used ‚-lactam antibiotics that resist hydrolysis by‚-lactamases. Recently, mutant ‚-lactamases that rapidly inactivate these drugs have emerged. To investigatewhy third-generation cephalosporins are relatively stable to wild-type class C ‚-lactamases and how mutantenzymes might overcome this, the structures of the class C ‚-lactamase AmpC in complex with the thirdgenerationcephalosporin ceftazidime and with a transition-state analogue of ceftazidime were determinedby X-ray crystallography to 2.0 and 2.3 Å resolution, respectively. Comparison of the acyl-enzyme structuresof ceftazidime and loracarbef, a ‚-lactam substrate, reveals that the conformation of ceftazidime in theactive site differs from that of substrates. Comparison of the structures of the acyl-enzyme intermediateand the transition-state analogue suggests that ceftazidime blocks formation of the tetrahedral transitionstate, explaining why it is an inhibitor of AmpC. Ceftazidime cannot adopt a conformation competent forcatalysis due to steric clashes that would occur with conserved residues Val211 and Tyr221. The X-raycrystal structure of the mutant ‚-lactamase GC1, which has improved activity against third-generationcephalosporins, suggests that a tandem tripeptide insertion in the ø loop, which contains Val211, hascaused a shift of this residue and also of Tyr221 that would allow ceftazidime and other third-generationcephalosporins to adopt a more catalytically competent conformation. These structural differences mayexplain the extended spectrum activity of GC1 against this class of cephalosporins. In addition, thecomplexed structure of the transition-state analogue inhibitor (Ki 20 nM) with AmpC reveals potentialopportunities for further inhibitor design.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris